NO922332L - Fremgangsmaate for fremstilling av faktoravhengige, humaneb-cellelinjer - Google Patents

Fremgangsmaate for fremstilling av faktoravhengige, humaneb-cellelinjer

Info

Publication number
NO922332L
NO922332L NO92922332A NO922332A NO922332L NO 922332 L NO922332 L NO 922332L NO 92922332 A NO92922332 A NO 92922332A NO 922332 A NO922332 A NO 922332A NO 922332 L NO922332 L NO 922332L
Authority
NO
Norway
Prior art keywords
cell lines
cross
dependent
humaneb
procedure
Prior art date
Application number
NO92922332A
Other languages
English (en)
Other versions
NO922332D0 (no
Inventor
Jacques Banchereau
Francoise Rousset
Original Assignee
Schering Plough Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Corp filed Critical Schering Plough Corp
Publication of NO922332D0 publication Critical patent/NO922332D0/no
Publication of NO922332L publication Critical patent/NO922332L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Control Of El Displays (AREA)
  • Photosensitive Polymer And Photoresist Processing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Silicon Polymers (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Light Receiving Elements (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Fremgangsmåte for etablering av faktoravhengige, humane B-cellelinjer som er i stand til å utskille immuno- globulin med en ønsket spesifisitet, og med evne til langvarig dyrkning. Frem- gangsmåten omfatter utvelgelse av en hvilende B-celle med immunoglobulin av den ønskede spesifisitet og dyrkning av den i nærvær av et middel som er i stand til å kryssbinde dens CD40-over- flateantigener. Langtidskultur krever vedvarende tilstedeværelse av kryss- bindingsmidlet. Kryssbindingsmidlet er fortrinnsvis et monoklonalt antistoff som er spesifikt for CD40-antigenet, presentert ved hjelp av ikke-repli- kerende pattedyrceller som uttrykker FcyRII.
NO92922332A 1989-12-14 1992-06-12 Fremgangsmaate for fremstilling av faktoravhengige, humaneb-cellelinjer NO922332L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19890403491 EP0434879A1 (en) 1989-12-14 1989-12-14 Method of making factor dependent human B cell lines
PCT/EP1990/002195 WO1991009115A1 (en) 1989-12-14 1990-12-13 Method of making factor-dependent human b cell lines

Publications (2)

Publication Number Publication Date
NO922332D0 NO922332D0 (no) 1992-06-12
NO922332L true NO922332L (no) 1992-06-12

Family

ID=8203014

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92922332A NO922332L (no) 1989-12-14 1992-06-12 Fremgangsmaate for fremstilling av faktoravhengige, humaneb-cellelinjer

Country Status (16)

Country Link
EP (2) EP0434879A1 (no)
JP (1) JPH0789910B2 (no)
AT (1) ATE135041T1 (no)
AU (1) AU655759B2 (no)
CA (1) CA2071886A1 (no)
DE (1) DE69025772T2 (no)
ES (1) ES2084146T3 (no)
FI (1) FI922655A7 (no)
IE (1) IE904498A1 (no)
IL (1) IL96639A0 (no)
MY (1) MY106561A (no)
NO (1) NO922332L (no)
NZ (1) NZ236425A (no)
OA (1) OA09701A (no)
WO (1) WO1991009115A1 (no)
ZA (1) ZA909778B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
EP0619323A1 (en) * 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
EP0659766A1 (en) * 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
ATE309267T1 (de) 1994-04-28 2005-11-15 Boehringer Ingelheim Pharma Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
US6465251B1 (en) 1996-11-13 2002-10-15 Dana-Farber Cancer Institute, Inc. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
WO1999022008A1 (en) * 1997-10-27 1999-05-06 Sumitomo Electric Industries, Ltd. Inducer for production of antigen-specific antibody, expression vector containing gene therefor, and method of inducing production of antigen-specific antibody
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
EP1322383B9 (en) 2000-10-02 2006-09-06 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
CA2617637C (en) 2005-08-02 2017-07-18 Xbiotech Inc. Diagnosis, treatment, and prevention of vascular disorders using il-1.alpha. autoantibodies
JP5762408B2 (ja) 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
EP2316920A1 (en) * 2009-10-30 2011-05-04 BioNTech AG Clonal expansion of B cells
BR112012031638B1 (pt) 2010-07-09 2021-01-12 Janssen Vaccines & Prevention B.V. anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado
EP2724157B1 (en) 2011-06-27 2017-03-08 Valneva Method for screening cells

Also Published As

Publication number Publication date
AU6901791A (en) 1991-07-18
JPH0789910B2 (ja) 1995-10-04
OA09701A (en) 1993-08-30
MY106561A (en) 1995-06-30
DE69025772D1 (de) 1996-04-11
FI922655A0 (fi) 1992-06-09
ES2084146T3 (es) 1996-05-01
NO922332D0 (no) 1992-06-12
EP0434879A1 (en) 1991-07-03
EP0505397B1 (en) 1996-03-06
AU655759B2 (en) 1995-01-12
WO1991009115A1 (en) 1991-06-27
FI922655A7 (fi) 1992-06-09
NZ236425A (en) 1993-02-25
CA2071886A1 (en) 1991-06-15
IE904498A1 (en) 1991-06-19
DE69025772T2 (de) 1997-02-06
EP0505397A1 (en) 1992-09-30
ATE135041T1 (de) 1996-03-15
ZA909778B (en) 1991-10-30
IL96639A0 (en) 1991-09-16
JPH05503214A (ja) 1993-06-03

Similar Documents

Publication Publication Date Title
NO922332L (no) Fremgangsmaate for fremstilling av faktoravhengige, humaneb-cellelinjer
DK154087C (da) Monoklonalt antistof, fremstilling heraf, hybrodimacellelinie til anvendelse ved fremstilling heraf, fremgangsmaade til anvendelse heraf samt diagnostisk praeparat indeholdende antistoffet
NO159888C (no) Monoklonalt antistoff.
DE3065072D1 (en) Process for producing antibodies to hepatitis virus and cell lines therefor
YU48442B (sh) Postupak za dobivanje monoklonalnog antitela okt 3
DK95687A (da) Fremgangsmaade til chargevis dyrkning af animalske celler
ES2131527T3 (es) Anticuerpos monoclonales contra c-kit.
NO159621C (no) Monoklonalt antistoff.
GB2000186A (en) Method of producing antibodies in vitro
NO803660L (no) Hybridcellelinje for fremstilling av monoklonalt antistoff til et antigen.
DK517180A (da) Hybrid cellelinie og fremgangsmaade til fremstilling og anvendelse deraf
ES8505406A1 (es) Procedimiento de obtener y aislar hibridomas secretores de anticuerpos, procedimiento de obtener anticuerpos y metodo de obtener polipeptidos
ATE288485T1 (de) Monoklonaler antikörper 4g8b4b12 gegen humanes flt3/flk2
DE69430313D1 (de) Monoklonale antikörper, die flk-2-rezeptoren erkennen, und die isolierung primitiver hämatopoietischer stammzellpopulationen
KR860007275A (ko) 모노클로날 항-알파-아밀라제 항체 및 그의 제법
DK439086A (da) Fremgangsmaader til anvendelse af cellelinier, der mangler humane klasseii histokompatibilitetsantigener
DE69431717D1 (de) BEHANDLUNG MITTELS EISEN-ENTZUG KOMBINIERT MIT IgG ANTIKÖRPER
SU1514768A1 (ru) ШТАММ ГИБРИДНЫХ КУЛЬТИВИРУЕМЫХ клеток животных ми5 миБсиьи5-продуцент моноклонального антитела к ре2 КОМБИНАНТНОМУ ФАКТОРУ НЕКРОЗА ОПУХОЛЕЙ-БЕТА ЧЕ
SU1529724A1 (ru) Штамм культивируемых гибридных клеток животного mus musculus - продуцент моноклонального антитела к термостабильному поверхностному антигену возбудителя сапа
ATE343596T1 (de) Humane monoklonale antikörper gegen inselzellantigen ia-2
SU1398393A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus, используемый для получения моноклональных антител к микобактериям туберкулеза
SU1692146A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus l. - продуцент моноклональных антител к 146 s-компоненту вируса ящура o
BG51639A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody towards antigenous determinant of strain " hantaan " of the virus of haemorrhagic fever with nephritic syndrome
SU1565021A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus - продуцент моноклональных антител к вирусу ящура 0-01618